DOCSLIB.ORG

1 SUPPLEMENTARY DATA Draft Medline Search – Pubmed Interface 1# "Puberty"[Mesh] OR (Puberties) OR (Pubertal Maturati

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 SUPPLEMENTARY DATA Draft Medline Search – Pubmed Interface 1# SUPPLEMENTARY DATA Draft Medline search – PubMed interface 1# "Puberty"[Mesh] OR (Puberties) OR (Pubertal Maturation) OR (Early Puberty) OR "Puberty, Precocious"[Mesh] OR (Precocious Puberty) OR "Precocious Puberty, Central" [Supplementary Concept] OR (Central Precocious Puberty) OR "Sexual precocity" [Supplementary Concept] OR (Idiopathic sexual precocity) OR (Familial precocious puberty) OR (Sexual Precocity) OR "Sexual Maturation"[Mesh] OR (Maturation, Sexual) OR (Maturation, Sex) OR (Sex Maturation) OR "Sexual Development"[Mesh] OR (Development, Sexual) OR (Sex Development) OR (Development, Sex) OR (Gonadal Disorder Maturation) OR (Pubertal Onset) OR "Menstruation Disturbances"[Mesh] OR (Precocious Menses) OR (Early Menses) OR (Early Menarche) OR (Precocious Menarche) OR (Disorders of Puberty) OR (Gonadotropin-Dependent Precocious Puberty) OR (Gonadotropin-Independent Precocious Puberty) OR (Isolated Precocious Thelarche) OR (Isolated Precocious Pubarche) OR (Isolated Precocious Menarche) 2# "Gonadotropin-Releasing Hormone"[Mesh] OR (Gonadotropin Releasing Hormone) OR (Luteinizing Hormone-Releasing Hormone) OR (Luteinizing Hormone Releasing Hormone) OR (GnRH) OR (Gonadoliberin) OR (Gonadorelin) OR (LFRH) OR (LH-FSH Releasing Hormone) OR (LH FSH Releasing Hormone) OR (LH-Releasing Hormone) OR (LH Releasing Hormone) OR (LH-RH) OR (LHFSH Releasing Hormone) OR (Releasing Hormone, LHFSH) OR (LHFSHRH) OR (LHRH) OR (Luliberin) OR (FSH-Releasing Hormone) OR (FSH Releasing Hormone) OR (Gn-RH) OR (Factrel) OR (Gonadorelin Acetate) OR (Kryptocur) OR (Cystorelin) OR (Dirigestran) OR (Gonadorelin Hydrochloride) OR (Luteinizing Hormone Releasing Hormone Analogue) OR (Gonadotropin Releasing Hormone Agonist) OR (GnRH Agonist) OR "Triptorelin Pamoate"[Mesh] OR "Nafarelin"[Mesh] OR "Leuprolide"[Mesh] OR "Triptorelin Pamoate"[Mesh] OR (Pamoate, Triptorelin) OR (CL-118532) OR (CL 118532) OR (CL118532) OR (Decapeptyl) OR (Beaufour Brand of Triptorelin Embonate) OR (Decapeptyl Depot) OR (Ipsen Brand of Triptorelin Embonate) OR (Decapeptyl Trimestral) OR (Trimestral, Decapeptyl) OR (Ferring Brand of Triptorelin Acetate) OR (Ipsen Brand of Triptorelin) OR (Triptorelin Ipsen Brand) OR (Beaufour Brand of Triptorelin) OR (Triptorelin Beaufour Brand) OR (Decapeptyl LP) OR (Triptorelin) OR (LHRH, Tryptophyl(6)-) OR (GnRH, Trp(6)-) OR (LHRH, Trp(6)-) OR 1 (6-D-Tryptophan-Luteinizing Hormone-Releasing Factor (Pig)) OR (D-Trp-6-LH-RH) OR (Wy-42462) OR (Wy 42462) OR (Wy42462) OR (AY-25650) OR (AY 25650) OR (AY25650) OR (Trelstar) OR (Watson Brand of Triptorelin Embonate) OR (Triptorelin Embonate) OR (Embonate, Triptorelin) OR "Nafarelin"[Mesh] OR (Synarel) OR (RS-94991- 298) OR (RS 94991 298) OR (RS94991298) OR (Nafarelin Acetate) OR (Nafarelin Acetate, Hydrate) OR (Nafarelin Monoacetate) OR "Leuprolide"[Mesh] OR (Leuprorelin) OR (Enantone) OR (Leuprolide Acetate) OR (Acetate, Leuprolide) OR (Leuprolide Monoacetate) OR (Monoacetate, Leuprolide) OR (Leuprolide, (L-Leu)-Isomer) OR (Lupron) OR (TAP- 144) OR (TAP 144) OR (TAP144) OR (A-43818) OR (A 43818) OR (A43818) OR (Leuprolide, (DL-Leu)-Isomer) OR "Goserelin"[Mesh] OR (ICI-118630) OR (ICI 118630) OR (ICI118630) OR (Zoladex) OR (Goserelin Acetate) OR (Acetate, Goserelin) OR "Buserelin"[Mesh] OR (Buserelin Acetate) OR (Acetate, Buserelin) OR (Suprefact) OR (Profact) OR (Aventis Brand of Buserelin Acetate) OR (Receptal) OR (Intervet Brand of Buserelin Acetate) OR (Tiloryth) OR (Hoechst Brand of Buserelin Acetate) OR (Suprecur) OR (Galenpharma Brand of Buserelin Acetate) OR (Bigonist) OR (Sanofi-Aventis Brand of Buserelin Acetate) OR (Sanofi Aventis Brand of Buserelin Acetate) OR (HOE-766) OR (HOE 766) OR (HOE766) 3# "Body Height"[Mesh] OR (Body Heights) OR (Height, Body) OR (Heights Body) OR (Final Height) OR (Target Height) OR (Predicted Height) OR (Growth) OR (Skeletal Growth) OR (Bone Maturation) OR (Auxological Anthropometry) OR (Adult Height) OR (Body Size) OR (Body Sizes) OR (Size, Body) OR (Sizes, Body) OR (Vertical Dimension) OR (Height) #4 (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ( placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT humans [mh]) #1 AND #2 AND #3 AND #4 2 Draft Embase search #1 'precocious puberty'/exp OR 'precocity, sexual' OR 'premature pubarche' OR 'premature puberty' OR 'premature thelarche' OR 'proeotia' OR 'proiotia' OR 'pubertas praecox' OR 'pubertas precox' OR 'puberty praecox' OR 'puberty, precocious' OR 'sex precocity' OR 'sexual precocity' OR ‘early puberty’ 2# 'gonadorelin'/exp OR '6 leucine 10 deglycine gonadotropin releasing factor ethylamide'/exp OR '[6 leucine 10 deglycine] gonadotropin releasing factor ethylamide'/exp OR 'ay 24, 031'/exp OR 'ay 24031'/exp OR 'ay24, 031'/exp OR 'ay24031'/exp OR 'cryptocur'/exp OR 'factrel'/exp OR 'fertagyl'/exp OR 'fertiral'/exp OR 'gn rh'/exp OR 'gnrh'/exp OR 'gnrh serono'/exp OR 'gonadoliberin'/exp OR 'gonadorelin hydrochloride'/exp OR 'gonadotrophin releasing factor'/exp OR 'gonadotrophin releasing hormone'/exp OR 'gonadotropin release factor'/exp OR 'gonadotropin releasing factor'/exp OR 'gonadotropin releasing hormone'/exp OR 'gonadotropin-releasing hormone'/exp OR 'hoe 471'/exp OR 'hoe471'/exp OR 'hoechst 471'/exp OR 'ici 88262'/exp OR 'ici88262'/exp OR 'kryptocur'/exp OR 'lh releasing hormone'/exp OR 'lrh'/exp OR 'lrh luteinising hormone releasing factor'/exp OR 'lrh luteinizing hormone releasing factor'/exp OR 'luforan'/exp OR 'luliberin'/exp OR 'luliberine'/exp OR 'lutal'/exp OR 'lutamin'/exp OR 'luteinising hormone release factor'/exp OR 'luteinising hormone releasing factor'/exp OR 'luteinising hormone releasing hormone'/exp OR 'luteinizing hormone release factor'/exp OR 'luteinizing hormone releasing factor'/exp OR 'luteinizing hormone releasing hormone'/exp OR 'pulstim'/exp OR 'relisorm'/exp OR 'gonadorelin agonist'/exp OR 'gnrh agonist'/exp OR 'gonadotropin releasing hormone agonist'/exp OR 'lhrh agonist'/exp OR 'luteinising hormone releasing hormone agonist'/exp OR 'luteinizing hormone releasing hormone agonist'/exp OR 'gonadorelin derivative'/exp OR 'gnrh derivative'/exp OR 'gonadoliberin analog'/exp OR 'gonadoliberin derivative'/exp OR 'gonadorelin analog'/exp OR 'gonadotropin releasing factor derivative'/exp OR 'gonadotropin releasing hormone analog'/exp OR 'gonadotropin releasing hormone derivative'/exp OR 'gonadotropin releasing hormone analogs'/exp OR 'lh releasing hormone analog'/exp OR 'lhrh'/exp OR 'hrh analog' OR 'lhrh derivative'/exp OR 'luliberin analog'/exp OR 'luliberin derivative'/exp OR 'luteinising hormone releasing factor derivative'/exp OR 'luteinising hormone releasing hormone analog'/exp OR 'luteinising hormone releasing hormone derivative'/exp OR 'luteinising releasing hormone analog'/exp OR 'luteinizing 3 hormone releasing factor derivative'/exp OR 'luteinizing hormone releasing hormone analog'/exp OR 'luteinizing hormone releasing hormone derivative'/exp OR 'luteinizing releasing hormone analog'/exp OR 'avorelin'/exp OR 'buserelin'/exp OR 'buserelin acetate'/exp OR 'dalarelin'/exp OR 'deslorelin'/exp OR 'folligen'/exp OR 'gonadorelin acetate'/exp OR 'gonadorelin associated peptide'/exp OR 'gonadorelin associated peptide derivative'/exp OR 'gonadorelin[1-9] ethylamide[6 dextro tryptophan]'/exp OR 'gonadorelin[1-9][6 dextro alanine]'/exp OR 'gonadorelin[6 dextro [3 (2 naphthyl)alanine] 10 azaglycine]'/exp OR 'gonadorelin[6 dextro lysine] 2 pyrrolinodoxorubicin'/exp OR 'gonadorelin[6 medphalan]'/exp OR 'goserelin or histrelin or leuprorelin' OR 'leuprorelin plus norethisterone acetate'/exp OR 'lutrelin'/exp OR 'nafarelin'/exp OR 'nafarelin acetate'/exp OR 'ovurelin'/exp OR 'peforelin'/exp OR 'triptorelin'/exp OR 'zoptarelin doxorubicin'/exp) #3 'height'/exp OR 'body height'/exp OR 'body length'/exp OR 'height, body'/exp OR 'length, body'/exp OR 'stature'/exp) #1 AND #2 AND #3 Draft Lilacs search – Virtual Health Library interface 1# MH:"Puberdade Precoce" OR (Early Puberty) OR MH:C19.391.693$ 2# MH:"Hormônio Liberador de Gonadotropina" OR (Hormônio Liberador do FSH) OR GnRH OR Gonadoliberina OR Gonadorrelina OR (Hormônio Liberador de LH-FSH) OR LHRH OR Luliberina OR (Hormônio Liberador de Hormônio Luteinizante) OR MH:D06.472.699.327.740.320$ OR MH:D12.644.400.400.740.320$ OR MH:D12.644.456.460$ OR MH:D12.644.548.365.740.320$ OR MH:D12.776.641.650.405.740.320$ OR MH:"Busserrelina" OR MH:D06.472.699.327.740.320.100$ OR MH:D12.644.400.400.740.320.100$ OR MH:D12.644.456.460.150$ OR MH:D12.644.548.365.740.320.100$ OR MH:D12.776.641.650.405.740.320.100$ OR MH:"Gosserrelina" OR MH:D06.472.699.327.740.320.340$ OR MH:D12.644.400.400.740.320.340$ OR MH:D12.644.456.460.315$ OR MH:D12.644.548.365.740.320.340$ OR MH:D12.776.641.650.405.740.320.340$ OR MH:"Leuprolida" OR MH:D06.472.699.327.740.320.400$ OR MH:D12.644.400.400.740.320.400$ OR MH:D12.644.456.460.480$ OR MH:D12.644.548.365.740.320.400$ OR MH:D12.776.641.650.405.740.320.400$ OR MH:"Nafarelina" OR MH:D06.472.699.327.740.320.580$ OR MH:D12.644.400.400.740.320.580$ OR 4 MH:D12.644.456.460.600$ OR MH:D12.644.548.365.740.320.580$
Load more

Recommended publications
  • Study Protocol and Documented in the Subject Dispensing Log
    Protocol Title of trial: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism NCT number: NCT01976728 Sponsor trial code: 000070 Date: 06 Dec 2017 Gonadorelin Acetate, FE Trial Code: 000070 Date: 06 Dec 2017 999037, FE 999903 E-Protocol Amendment-21975;1.0 No Specified Dosage Form and Strength Supersedes: None Clinical Trial Protocol - Amendment 7 Page 1 of 82 CLINICAL TRIAL PROTOCOL A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism Trial Code 000070 Consolidated Protocol Incorporating Amendments 1-7 IND Number: 22,278 Investigational Medicinal Product: LutrePulse OmniPod Indication: Primary Hypothalamic Amenorrhea Phase: III Name and Address of Sponsor: Ferring International Pharmascience Center U.S., Inc. 100 Interpace Parkway Parsippany, NJ 07054 P: 973-796-1600 F: 973-796-1660 GCP Statement: This trial will be performed in compliance with GCP. The information in this document is confidential and is proprietary to Ferring International Pharmascience Center U.S. or another company within the Ferring Group. It is understood that information in this document shall not be disclosed to any third party, in any form, without prior written consent
    [Show full text]
  • Hormones and Breeding
    IN-DEPTH: REPRODUCTIVE ENDOCRINOLOGY Hormones and Breeding Carlos R.F. Pinto, MedVet, PhD, Diplomate ACT Author’s address: Theriogenology and Reproductive Medicine, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210; e-mail: [email protected]. © 2013 AAEP. 1. Introduction affected by PGF treatment to induce estrus. In The administration of hormones to mares during other words, once luteolysis takes place, whether breeding management is an essential tool for equine induced by PGF treatment or occurring naturally, practitioners. Proper and timely administration of the events that follow (estrus behavior, ovulation specific hormones to broodmares may be targeted to and fertility) are essentially similar or minimally prevent reproductive disorders, to serve as an aid to affected (eg, decreased signs of behavioral estrus). treating reproductive disorders or hormonal imbal- Duration of diestrus and interovulatory intervals ances, and to optimize reproductive efficiency, for are shortened after PGF administration.1 The example, through induction of estrus or ovulation. equine corpus luteum (CL) is responsive to PGF These hormones, when administered exogenously, luteolytic effects any day after ovulation; however, act to control the duration and onset of the different only CL Ͼ5 days are responsive to one bolus injec- stages of the estrous cycle, specifically by affecting tion of PGF.2,3 Luteolysis or antiluteogenesis can duration of luteal function, hastening ovulation es- be reliably achieved in CL Ͻ5 days only if multiple pecially for timed artificial insemination and stimu- PGF treatments are administered. For that rea- lating myometrial activity in mares susceptible to or son, it became a widespread practice to administer showing delayed uterine clearance.
    [Show full text]
  • Leuprolide Acetate)
    For Pediatric Use LUPRON® INJECTION (leuprolide acetate) Rx only DESCRIPTION Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. The chemical name is 5- oxo -L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl- N-ethyl-L-prolinamide acetate (salt) with the following structural formula: LUPRON INJECTION is a sterile, aqueous solution intended for daily subcutaneous injection. It is available in a 2.8 mL multiple dose vial containing leuprolide acetate (5 mg/mL), sodium chloride, USP (6.3 mg/mL) for tonicity adjustment, benzyl alcohol, NF as a preservative (9 mg/mL), and water for injection, USP. The pH may have been adjusted with sodium hydroxide, NF and/or acetic acid, NF. CLINICAL PHARMACOLOGY Leuprolide acetate, a GnRH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously and in therapeutic doses. Animal and human studies indicate that following an initial stimulation of gonadotropins, chronic administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect is reversible upon discontinuation of drug therapy. Leuprolide acetate is not active when given orally. Pharmacokinetics A pharmacokinetic study of leuprolide acetate in children has not been performed. Absorption Page 1 In adults, bioavailability by subcutaneous administration is comparable to that by intravenous administration. Distribution The mean steady-state volume of distribution of leuprolide following intravenous bolus administration to healthy adult male volunteers was 27 L. In vitro binding to human plasma proteins ranged from 43% to 49%.
    [Show full text]
  • B Commission Regulation (Eu)
    02010R0037 — EN — 29.09.2018 — 035.001 — 1 This text is meant purely as a documentation tool and has no legal effect. The Union's institutions do not assume any liability for its contents. The authentic versions of the relevant acts, including their preambles, are those published in the Official Journal of the European Union and available in EUR-Lex. Those official texts are directly accessible through the links embedded in this document ►B COMMISSION REGULATION (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin (Text with EEA relevance) (OJ L 15, 20.1.2010, p. 1) Amended by: Official Journal No page date ►M1 Commission Regulation (EU) No 758/2010 of 24 August 2010 L 223 37 25.8.2010 ►M2 Commission Regulation (EU) No 759/2010 of 24 August 2010 L 223 39 25.8.2010 ►M3 Commission Regulation (EU) No 761/2010 of 25 August 2010 L 224 1 26.8.2010 ►M4 Commission Regulation (EU) No 890/2010 of 8 October 2010 L 266 1 9.10.2010 ►M5 Commission Regulation (EU) No 914/2010 of 12 October 2010 L 269 5 13.10.2010 ►M6 Commission Regulation (EU) No 362/2011 of 13 April 2011 L 100 26 14.4.2011 ►M7 Commission Regulation (EU) No 363/2011 of 13 April 2011 L 100 28 14.4.2011 ►M8 Commission Implementing Regulation (EU) No 84/2012 of 1 L 30 1 2.2.2012 February 2012 ►M9 Commission Implementing Regulation (EU) No 85/2012 of 1 L 30 4 2.2.2012 February 2012 ►M10 Commission Implementing Regulation (EU) No 86/2012 of 1 L 30 6 2.2.2012 February 2012 ►M11 Commission
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Prescribing Support Information GONADORELIN ANALOGUES To
    Pending CCG approval Prescribing Support Information GONADORELIN ANALOGUES to achieve feminisation or masculinisation following assessment and diagnosis of Gender Incongruence at the NHS commissioned Cheshire and Merseyside Gender Identity Service AMBER patient retained by specialist Your patient has been identified as being suitable to receive a gonadorelin analogue in accordance with the indications detailed below. They have been started on treatment and have been reviewed to assess the efficacy and adverse effects of the treatment by the specialist team. Prescribing has been retained by the specialist team for the first 6-12 months until stabilisation of the dose and monitoring requirements has been achieved. Triptorelin is the Pan Mersey first line choice. Gonadorelin analogue treatment will continue until gonadectomy. Gonadorelin analogue treatment has been considered as appropriate for prescribing in primary care and the information contained in this document has been provided to support you to prescribe the medicine for your patient in the community. Your patient’s dose is now stable and is detailed in the attached clinic letter. There has been a significant amount of experience in the treatment of gender incongruence over the last 40 years, using several well-established hormonal protocols, and the available evidence demonstrates that, for carefully selected patients, hormone therapy is a safe and effective means of alleviating the potentially debilitating condition of gender dysphoria.1.2 Although these medicines are not licensed for the treatment of gender incongruence, they are medicines with which GPs may be familiar. Your patient will remain under the care of a specialist team within Cheshire and Merseyside Gender Identity Collaborative (CMAGIC) whilst receiving this medicine and will be able to be fast tracked back into the gender service if there are any issues.
    [Show full text]
  • Hertfordshire Medicines Management Committee (Hmmc) Nafarelin for Endometriosis Amber Initiation – Recommended for Restricted Use
    HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) NAFARELIN FOR ENDOMETRIOSIS AMBER INITIATION – RECOMMENDED FOR RESTRICTED USE Name: What it is Indication Date Decision NICE / SMC generic decision status Guidance (trade) last revised Nafarelin A potent agonistic The hormonal December Final NICE NG73 2mg/ml analogue of management of 2020 Nasal Spray gonadotrophin endometriosis, (Synarel®) releasing hormone including pain relief and (GnRH) reduction of endometriotic lesions HMMC recommendation: Amber initiation across Hertfordshire (i.e. suitable for primary care prescribing after specialist initiation) as an option in endometriosis Background Information: Gonadorelin analogues (or gonadotrophin-releasing hormone agonists [GnRHas]) include buserelin, goserelin, leuprorelin, nafarelin and triptorelin. The current HMMC decision recommends triptorelin as Decapeptyl SR® injection as the gonadorelin analogue of choice within licensed indications (which include endometriosis) link to decision. A request was made by ENHT to use nafarelin nasal spray as an alternative to triptorelin intramuscular injection during the COVID-19 pandemic. The hospital would provide initial 1 month supply, then GPs would continue for further 5 months as an alternative to the patient attending for further clinic appointments for administration of triptorelin. Previously at ENHT, triptorelin was the only gonadorelin analogue on formulary for gynaecological indications. At WHHT buserelin nasal spray 150mcg/dose is RED (hospital only) for infertility & endometriosis indications. Nafarelin nasal spray 2mg/ml is licensed for: . The hormonal management of endometriosis, including pain relief and reduction of endometriotic lesions. Use in controlled ovarian stimulation programmes prior to in-vitro fertilisation, under the supervision of an infertility specialist. Use of nafarelin in endometriosis aims to induce chronic pituitary desensitisation, which gives a menopause-like state maintained over many months.
    [Show full text]
  • Report Name:Ukraine's Mrls for Veterinary Drugs
    Voluntary Report – Voluntary - Public Distribution Date: November 05,2020 Report Number: UP2020-0051 Report Name: Ukraine's MRLs for Veterinary Drugs Country: Ukraine Post: Kyiv Report Category: FAIRS Subject Report Prepared By: Oleksandr Tarassevych Approved By: Robin Gray Report Highlights: Ukraine adopted several maximum residue levels (MRLs) for veterinary drugs, coccidiostats and histomonostats in food products of animal origin. Ukraine also adopted a list of drugs residues that are not allowed in food products. THIS REPORT CONTAINS ASSESSMENTS OF COMMODITY AND TRADE ISSUES MADE BY USDA STAFF AND NOT NECESSARILY STATEMENTS OF OFFICIAL U.S. GOVERNMENT POLICY The Office of Agricultural Affairs of USDA/Foreign Agricultural Service in Kyiv, Ukraine prepared this report for U.S. exporters of domestic food and agricultural products. While every possible care was taken in the preparation of this report, information provided may not be completely accurate either because policies have changed since the time this report was written, or because clear and consistent information about these policies was not available. It is highly recommended U.S. exporters verify the full set of import requirements with their foreign customers, who are normally best equipped to research such matters with local authorities, before any goods are shipped. This FAIRS Subject Report accompanies other reports on Maximum, Residue Limits established by Ukraine in 2020. Related reports could be found under the following links: 1.) Ukraine's MRLs for Microbiological Contaminants_Kyiv_Ukraine_04-27-2020 2.) Ukraine's MRLs for Certain Contaminants_Kyiv_Ukraine_03-06-2020 Food Products of animal origin and/or ingredients of animal origin are not permitted in the Ukrainian market if they contain certain veterinary drugs residues in excess of the maximum residue levels established in Tables 1 and 2.
    [Show full text]
  • Statistical Analysis Plan
    Title: An Open label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty NCT Number: NCT02427958 SAP Approve Date: 01 June 2017 Certain information within this Statistical Analysis Plan has been redacted (ie, specific content is masked irreversibly from view with a black/blue bar) to protect either personally identifiable (PPD) information or company confidential information (CCI). This may include, but is not limited to, redaction of the following: Named persons or organizations associated with the study. Proprietary information, such as scales or coding systems, which are considered confidential information under prior agreements with license holder. • Other information as needed to protect confidentiality of Takeda or partners, personal information, or to otherwise protect the integrity of the clinical study. Takeda Statistical Analysis Plan Leuprorelin-4001 Version: 1.0 An Open label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty Leuprorelin-4001, Leuprorelin in the Treatment of Central Precocious Puberty Statistical Analysis Plan Version: 1.0 Date: 01 June 2017 1 PPD PPD Takeda Statistical Analysis Plan Leuprorelin-4001 Version: 1.0 TABLE OF CONTENTS ABBREVIATIONS ........................................................................................................................ 6 1. INTRODUCTION ...............................................................................................................
    [Show full text]
  • Fully Automated Dried Blood Spot Sample Preparation Enables the Detection of Lower Molecular Mass Peptide and Non-Peptide Doping Agents by Means of LC-HRMS
    Analytical and Bioanalytical Chemistry (2020) 412:3765–3777 https://doi.org/10.1007/s00216-020-02634-4 RESEARCH PAPER Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS Tobias Lange1 & Andreas Thomas1 & Katja Walpurgis1 & Mario Thevis1,2 Received: 10 December 2019 /Revised: 26 March 2020 /Accepted: 31 March 2020 # The Author(s) 2020 Abstract The added value of dried blood spot (DBS) samples complementing the information obtained from commonly routine doping control matrices is continuously increasing in sports drug testing. In this project, a robotic-assisted non-destructive hematocrit measurement from dried blood spots by near-infrared spectroscopy followed by a fully automated sample preparation including strong cation exchange solid-phase extraction and evaporation enabled the detection of 46 lower molecular mass (< 2 kDa) peptide and non-peptide drugs and drug candidates by means of LC-HRMS. The target analytes included, amongst others, agonists of the gonadotropin-releasing hormone receptor, the ghrelin receptor, the human growth hormone receptor, and the antidiuretic hormone receptor. Furthermore, several glycine derivatives of growth hormone–releasing peptides (GHRPs), argu- ably designed to undermine current anti-doping testing approaches, were implemented to the presented detection method. The initial testing assay was validated according to the World Anti-Doping Agency guidelines with estimated LODs between 0.5 and 20 ng/mL. As a proof of concept, authentic post-administration specimens containing GHRP-2 and GHRP-6 were successfully analyzed. Furthermore, DBS obtained from a sampling device operating with microneedles for blood collection from the upper arm were analyzed and the matrix was cross-validated for selected parameters.
    [Show full text]
  • Nafarelin Acetate (Synarel) Reference Number: PA.CP.PHAR.174 Effective Date: 01/18 Coding Implications Last Review Date: 10/18 Revision Log
    Clinical Policy: Nafarelin Acetate (Synarel) Reference Number: PA.CP.PHAR.174 Effective Date: 01/18 Coding Implications Last Review Date: 10/18 Revision Log Description The intent of the criteria is to ensure that patients follow selection elements established by Pennsylvania Health and Wellness® medical policy for the use of nafarelin acetate (Synarel®). FDA Approved Indication(s) Synarel is indicated for: • Treatment of CPP (gonadotropin-dependent precocious puberty) in children of both sexes; • Management of endometriosis, including pain relief and reduction of endometriotic lesions. Policy/Criteria It is the policy of Pennsylvania Health and Wellness that Synarel is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Central Precocious Puberty (must meet all): 1. Diagnosis of central precocious puberty confirmed by all of the following (a through c): a. Elevated basal luteinizing hormone (LH) level > 0.2 - 0.3 mIU/L (dependent on type of assay used) and/or elevated leuprolide-stimulated LH level > 3.3 - 5 IU/I (dependent on type of assay used); b. Difference between bone age and chronological age was > 1 year (bone age- chronological age; c. Age at onset of secondary sex characteristics is < 8 years if female, or < 9 years if male; 2. Member meets the following age requirements: a. Female: 2 - 11 years; b. Male: 2 - 12 years; 3. Prescribed by or in consultation with a pediatric endocrinologist; 4. Dose does not exceed 1800 micrograms per day. Approval duration: 12 months B. Endometriosis (must meet all): 1. Diagnosis of endometriosis; 2. Prescribed by or in consultation with a gynecologist; 3.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]